These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25989949)

  • 21. PPAR-γ Agonists for the Treatment of Major Depression: A Review.
    Colle R; de Larminat D; Rotenberg S; Hozer F; Hardy P; Verstuyft C; Fève B; Corruble E
    Pharmacopsychiatry; 2017 Mar; 50(2):49-55. PubMed ID: 27978584
    [No Abstract]   [Full Text] [Related]  

  • 22. Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders.
    de Melo LGP; Nunes SOV; Anderson G; Vargas HO; Barbosa DS; Galecki P; Carvalho AF; Maes M
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Aug; 78():34-50. PubMed ID: 28438472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies.
    Sharma AN; da Costa e Silva BF; Soares JC; Carvalho AF; Quevedo J
    J Affect Disord; 2016 Jun; 197():9-20. PubMed ID: 26956384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebral metabolic patterns in untreated postmenopausal women with major depressive disorder.
    Rasgon NL; Kenna HA; Geist C; Small G; Silverman D
    Psychiatry Res; 2008 Oct; 164(1):77-80. PubMed ID: 18707852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Divergent Urinary Metabolic Phenotypes between Major Depressive Disorder and Bipolar Disorder Identified by a Combined GC-MS and NMR Spectroscopic Metabonomic Approach.
    Chen JJ; Zhou CJ; Liu Z; Fu YY; Zheng P; Yang DY; Li Q; Mu J; Wei YD; Zhou JJ; Huang H; Xie P
    J Proteome Res; 2015 Aug; 14(8):3382-9. PubMed ID: 26168936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surrogate markers of treatment outcome in major depressive disorder.
    Papakostas GI
    Int J Neuropsychopharmacol; 2012 Jul; 15(6):841-54. PubMed ID: 21813045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major depression and its treatment: microRNAs as peripheral biomarkers of diagnosis and treatment response.
    Lopez JP; Kos A; Turecki G
    Curr Opin Psychiatry; 2018 Jan; 31(1):7-16. PubMed ID: 29076893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can neurophysiologic measures serve as biomarkers for the efficacy of repetitive transcranial magnetic stimulation treatment of major depressive disorder?
    Kobayashi B; Cook IA; Hunter AM; Minzenberg MJ; Krantz DE; Leuchter AF
    Int Rev Psychiatry; 2017 Apr; 29(2):98-114. PubMed ID: 28362541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hair cortisol as a marker of hypothalamic-pituitary-adrenal Axis activity in female patients with major depressive disorder.
    Pochigaeva K; Druzhkova T; Yakovlev A; Onufriev M; Grishkina M; Chepelev A; Guekht A; Gulyaeva N
    Metab Brain Dis; 2017 Apr; 32(2):577-583. PubMed ID: 28064407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteomics Approach for Biomarker Research in Major Depression: Antidepressant Effects.
    Huang TL; Lo LH
    Curr Drug Metab; 2018; 19(6):502-512. PubMed ID: 29623831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Extrinsic Coagulation Pathway: a Biomarker for Suicidal Behavior in Major Depressive Disorder.
    Yang Y; Chen J; Liu C; Fang L; Liu Z; Guo J; Cheng K; Zhou C; Zhan Y; Melgiri ND; Zhang L; Zhong J; Chen J; Rao C; Xie P
    Sci Rep; 2016 Sep; 6():32882. PubMed ID: 27605454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence.
    Nunes SO; Vargas HO; Prado E; Barbosa DS; de Melo LP; Moylan S; Dodd S; Berk M
    Neurosci Biobehav Rev; 2013 Sep; 37(8):1336-45. PubMed ID: 23660457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants.
    Gibbons AS; Jeon WJ; Scarr E; Dean B
    Int J Neuropsychopharmacol; 2016 Apr; 19(4):. PubMed ID: 26475745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focus on GABA(A) receptor function. A comparative analysis of in vivo imaging studies in neuropsychiatric disorders.
    Nikolaus S; Hautzel H; Müller HW
    Nuklearmedizin; 2014; 53(6):227-37. PubMed ID: 25483111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory markers and cortisol parameters across depressive subtypes in an older cohort.
    Veltman EM; Lamers F; Comijs HC; Stek ML; van der Mast RC; Rhebergen D
    J Affect Disord; 2018 Jul; 234():54-58. PubMed ID: 29522944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change.
    Lopresti AL; Maes M; Meddens MJ; Maker GL; Arnoldussen E; Drummond PD
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):38-50. PubMed ID: 25523883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An altered peripheral IL6 response in major depressive disorder.
    Money KM; Olah Z; Korade Z; Garbett KA; Shelton RC; Mirnics K
    Neurobiol Dis; 2016 May; 89():46-54. PubMed ID: 26804030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is plasminogen activator inhibitor-1 a physiological bottleneck bridging major depressive disorder and cardiovascular disease?
    Savoy C; Van Lieshout RJ; Steiner M
    Acta Physiol (Oxf); 2017 Apr; 219(4):715-727. PubMed ID: 27246986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiosomatic complaints, immune-inflammatory pathways, and serotonin-related mood symptoms: relevance for tryptophan-related challenge procedures and clinical considerations with respect to the DSM-V.
    von Polier GG; Zepf FD
    Acta Psychiatr Scand; 2014 Feb; 129(2):98-9. PubMed ID: 24117193
    [No Abstract]   [Full Text] [Related]  

  • 40. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.
    Trivedi MH; McGrath PJ; Fava M; Parsey RV; Kurian BT; Phillips ML; Oquendo MA; Bruder G; Pizzagalli D; Toups M; Cooper C; Adams P; Weyandt S; Morris DW; Grannemann BD; Ogden RT; Buckner R; McInnis M; Kraemer HC; Petkova E; Carmody TJ; Weissman MM
    J Psychiatr Res; 2016 Jul; 78():11-23. PubMed ID: 27038550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.